Anna Laurell
About
Anna Laurell is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Anna Laurell has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 20 papers in Oncology and 17 papers in Genetics. Recurrent topics in Anna Laurell's work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (9 papers). Anna Laurell is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (9 papers). Anna Laurell collaborates with scholars based in Sweden, Norway and Denmark. Anna Laurell's co-authors include Mats Jerkeman, Arne Kolstad, Christer Sundström, Gregor Verhoef, Riikka Räty, Michael Crump, Raoul Herbrecht, Bertrand Coiffier, Laurence Moore and Andrew Strahs and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.
In The Last Decade
Anna Laurell
44 papers receiving 1.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anna Laurell Sweden | 19 | 947 | 778 | 666 | 529 | 427 | 45 | 1.9k | ||
| Hye Jin Kang South Korea | 26 | 905 1.0× | 822 1.1× | 254 0.4× | 235 0.4× | 461 1.1× | 120 | 1.8k | ||
| Xiaonan Hong China | 20 | 930 1.0× | 1.0k 1.3× | 309 0.5× | 248 0.5× | 416 1.0× | 71 | 1.7k | ||
| Osnat Bairey Israel | 27 | 1.4k 1.4× | 598 0.8× | 1.2k 1.8× | 542 1.0× | 247 0.6× | 103 | 2.5k | ||
| B. Audhuy France | 20 | 492 0.5× | 986 1.3× | 375 0.6× | 437 0.8× | 316 0.7× | 48 | 1.9k | ||
| C. Portlock United States | 21 | 1.1k 1.1× | 732 0.9× | 438 0.7× | 160 0.3× | 367 0.9× | 36 | 1.6k | ||
| Jörg Kalla Germany | 25 | 1.6k 1.7× | 1.0k 1.3× | 723 1.1× | 341 0.6× | 271 0.6× | 40 | 2.0k | ||
| Thomas Melchardt Austria | 23 | 396 0.4× | 559 0.7× | 486 0.7× | 380 0.7× | 226 0.5× | 93 | 1.4k | ||
| Enrico Derenzini Italy | 25 | 1.2k 1.3× | 766 1.0× | 344 0.5× | 405 0.8× | 275 0.6× | 99 | 1.9k | ||
| Evelyne Callet‐Bauchu France | 26 | 1.8k 1.8× | 906 1.2× | 1.1k 1.7× | 542 1.0× | 157 0.4× | 62 | 2.6k | ||
| Nicola Di Renzo Italy | 24 | 944 1.0× | 681 0.9× | 631 0.9× | 329 0.6× | 277 0.6× | 98 | 1.9k |
Countries citing papers authored by Anna Laurell
Since
Specialization
Citations
This map shows the geographic impact of Anna Laurell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Laurell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Laurell more than expected).
Fields of papers citing papers by Anna Laurell
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anna Laurell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Laurell. The network helps show where Anna Laurell may publish in the future.
Co-authorship network of co-authors of Anna Laurell
This figure shows the co-authorship network connecting the top 25 collaborators of Anna Laurell. A scholar is included among the top collaborators of Anna Laurell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Laurell. Anna Laurell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Liu, Lisa L., Anders Ullén, Anna Laurell, et al.. (2025). Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab. Acta Oncologica. 64. 1355–1364.
2.
Verbiené, Ingrida, Anna Laurell, Karin Söderkvist, et al.. (2023). Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era. Clinical Genitourinary Cancer. 21(6). e438–e448.
3.
Lindskog, Magnus, Anna Laurell, Anders Kjellman, et al.. (2022). Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 40. 38–45.
4.
Eskelund, Christian Winther, Arne Kolstad, Anna Laurell, et al.. (2021). Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experience. Hematological Oncology. 40(1). 23–31.
5.
Jerkeman, Mats, Christian Winther Eskelund, Martin Hutchings, et al.. (2018). Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Haematology. 5(3). e109–e116.
6.
Laurell, Anna, Maria Lönnemark, Einar Brekkan, et al.. (2017). Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 5(1). 52–52.
7.
Kolstad, Arne, Anna Laurell, Riikka Räty, et al.. (2016). Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood. 128(14). 1814–1820.
8.
Zur‐Mühlen, Bengt von, Hans Hagberg, Anna Laurell, et al.. (2016). Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation – experiences from a prospective, clinical, observational study. Acta Oncologica. 55(6). 774–781.
9.
Laurell, Anna, et al.. (2015). Whole body MRI, including diffusion-weighted imaging in follow-up of patients with testicular cancer. Acta Oncologica. 54(10). 1763–1769.
10.
Laurell, Anna, et al.. (2014). Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Medical Oncology. 31(3). 841–841.
11.
Farnebo, Jacob, Per Grybäck, Ulrika Harmenberg, et al.. (2014). Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC Cancer. 14(1). 408–408.
12.
Tandstad, Torgrim, Rune Smaaland, Arne Solberg, et al.. (2011). Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group. Journal of Clinical Oncology. 29(6). 719–725.
13.
Haugnes, Hege Sagstuen, Anna Laurell, Ulrika Stierner, et al.. (2011). High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer – a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncologica. 51(2). 168–176.
14.
Geisler, Christian H., et al.. (2009). Mantle cell lymphoma – does primary intensive immunochemotherapy improve overall survival for younger patients?. Leukemia & lymphoma. 50(8). 1249–1256.
15.
Walsh, Sarah H., Pawel Grabowski, Mattias Berglund, et al.. (2007). Telomere length and correlation with histopathogenesis in B‐cell leukemias/lymphomas. European Journal Of Haematology. 78(4). 283–289.
16.
Adde, Magdalena, Gunilla Enblad, Hans Hagberg, Christer Sundström, & Anna Laurell. (2006). Outcome for Young High-Risk Aggressive B-Cell Lymphoma Patients Treated with CHOEP-14 and Rituximab (R-CHOEP-14). Medical Oncology. 23(2). 283–294.
17.
Francis, Princy, Josefin Fernebro, Patrik Edén, et al.. (2005). Intratumor versus intertumor heterogeneity in gene expression profiles of soft‐tissue sarcomas. Genes Chromosomes and Cancer. 43(3). 302–308.
18.
Walsh, Sarah H., et al.. (2005). Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. Leukemia Research. 29(7). 729–734.
19.
Grabowski, Pawel, Magnus Hultdin, Karin Karlsson, et al.. (2005). Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood. 105(12). 4807–4812.
20.
Thelander, Emma Flordal, Sarah H. Walsh, Mia Thorsélius, et al.. (2004). Mantle cell lymphomas with clonal immunoglobulin V3–21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V genes. Modern Pathology. 18(3). 331–339.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hye Jin Kang Breakdown of academic impact, for papers by Xiaonan Hong Breakdown of academic impact, for papers by Osnat Bairey Breakdown of academic impact, for papers by B. Audhuy Breakdown of academic impact, for papers by C. Portlock Breakdown of academic impact, for papers by Jörg Kalla Breakdown of academic impact, for papers by Thomas Melchardt Breakdown of academic impact, for papers by Enrico Derenzini Breakdown of academic impact, for papers by Evelyne Callet‐Bauchu Breakdown of academic impact, for papers by Nicola Di Renzo